HMGB1在自身免疫和炎症疾病中的作用及研究进展

高迁移率族蛋白1 (High Mobility Group Box-1 Protein,HMGB1)是一种细胞核内的非组蛋白,其作为促炎介质或预警蛋白可以诱导自身免疫和炎症疾病的发生.HMGB1通常位于细胞核内,在细胞活化和死亡时,可以转运到细胞质或胞外基质中.细胞活化过程中,HMGB1经历了翻译后修饰,活性会随着半胱氨酸残基的氧化态变化而变化.HMGB1能直接作用于细胞,也能与细胞因子或其他内外源性因子形成免疫调控复合物间接作用于细胞.对于风湿性关节炎,关节滑液中胞核外的HMGB1表达上升,对HMGB1进行阻断可以减轻疾病的症状.对于牙周炎,牙龈组织中HMGB1呈高表达,并与炎症因子的释放相关.总之,HMGB1可能作为一种重要的促炎介质或预警蛋白出现在自身免疫和炎症疾病中,有望成为新的治疗靶点.     

The Role of Macrophage Polarization in Infectious and Inflammatory Diseases

Macrophages, found in circulating blood as well as integrated into several tissues and organs throughout the body, represent an important first line of defense against disease and a necessary component of healthy tissue homeostasis. Additionally, macrophages that arise from the differentiation of monocytes recruited from the blood to inflamed tissues play a central role in regulating local inflammation. Studies of macrophage activation in the last decade or so have revealed that these cells adopt a staggering range of phenotypes that are finely tuned responses to a variety of different stimuli, and that the resulting subsets of activated macrophages play critical roles in both progression and resolution of disease. This review summarizes the current understanding of the contributions of differentially polarized macrophages to various infectious and inflammatory diseases and the ongoing effort to develop novel therapies that target this key aspect of macrophage biology.     

Th细胞亚群在自身免疫病的发病及治疗中作用的实验研究进展

本文回顾了Ｔｈ细胞亚群的功能、交互调节、影响其分化的因素以及Ｔｈ细胞亚群在自身免疫病发病中的可能作用;概括了通过调节Ｔｈ细胞亚群来治疗自身免疫病的方法,包括：上调ＣＤ１ｄ治疗、给予相关细胞因子治疗、佐剂治疗、用抗细胞因子、细胞因子受体、ＣＤ４０配体和Ｂ７分子的单克隆抗体治疗以及ＣＴＬＡ和ＣＴＬＡＩｇ治疗。这些方法为自身免疫病的治疗提供了新的思路。     

Microbiota: A Missing Link in The Pathogenesis of Chronic Lung Inflammatory Diseases

Chronic respiratory diseases account for high morbidity and mortality, with asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF) being the most prevalent globally. Even though the diseases increase in prevalence, the exact underlying mechanisms have still not been fully understood. Despite their differences in nature, pathophysiologies, and clinical phenotypes, a growing body of evidence indicates that the presence of lung microbiota can shape the pathogenic processes underlying chronic inflammation, typically observed in the course of the diseases. Therefore, the characterization of the lung microbiota may shed new light on the pathogenesis of these diseases. Specifically, in chronic respiratory tract diseases, the human microbiota may contribute to the disease’s development and severity. The present review explores the role of the microbiota in the area of chronic pulmonary diseases, especially COPD, asthma, and CF.     

The Involvement of Immune Semaphorins in the Pathogenesis of Inflammatory Bowel Diseases (IBDs)

ResultsThe percentage (%) of T regulatory cells (Tregs) expressing sema3A in patients with active CD (64.5% ±14.49%) and active UC (49.8% ±16.45%) was significantly lower when compared to that of healthy controls (88.7% ±3.6%, p< 0.001 and p< 0.0001, respectively). This expression was seen to be in negative correlation with CD activity. Serum levels of Sema4A were significantly lower in patients with CD and UC when compared to that of controls (5.69±1.48ng\ml for CD, 5.26±1.23 ng/ml for UC patients vs 9.74±2.73ng/ml for normal controls, P<0.001). Sema4A was highly expressed in lymphocytes of the lamina propria of CD and UC patients but absent in patients with diverticulitis or in normal individuals.ConclusionsAltered % of Tregs expressing sema3A in patients with inflammatory bowel diseases (IBD) is partially responsible for their failure in preventing CD4+ effector T cell induced inflammation in IBD in peripheral blood. The increased expression of sema4A in bowel biopsies from CD and UC patients is suggestive of its central role in regulating local tissue inflammation in the bowel.     

HMGB1 in Development and Diseases of the Central Nervous System

High mobility group box 1 (HMGB1) is widely expressed in cells of vertebrates in two forms: a nuclear "architectural" factor and a secreted inflammatory factor. During early brain development, HMGB1 displays a complex temporal and spatial distribution pattern in the central nervous system. It facilitates neurite outgrowth and cell migration critical for processes, such as forebrain development. During adulthood, HMGB1 serves to induce neuroinflammation after injury, such as lesions in the spinal cord and brain. Receptor for advanced glycation end products and Toll-like receptors signal transduction pathways mediate HMGB1-induced neuroinflammation and necrosis. Increased levels of endogenous HMGB1 have also been detected in neurodegenerative diseases. However, in Huntington's disease, HMGB1 has been reported to protect neurons through activation of apurinic/apyrimidinic endonuclease and 5'-flap endonuclease-1, whereas in other neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, HMGB1 serves as a risk factor for memory impairment, chronic neurodegeneration, and progression of neuroinflammation. Thus, HMGB1 plays important and double-edged roles during neural development and neurodegeneration. The HMGB1-mediated pathological mechanisms have remained largely elusive. Knowledge of these mechanisms is likely to lead to therapeutic targets for neurological diseases.     

Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases

Interleukin (IL)-6, a cytokine featuring redundancy and pleiotropic activity, contributes to host defense against acute environmental stress, while dysregulated persistent IL-6 production has been demonstrated to play a pathological role in various autoimmune and chronic inflammatory diseases. Targeting IL-6 is thus a rational approach to the treatment of these diseases. Indeed, clinical trials of tocilizumab, a humanized anti-IL-6 receptor antibody have verified its efficacy and tolerable safety for patients with rheumatoid arthritis, Castleman''s disease and systemic juvenile idiopathic arthritis, resulting in approval of this innovative biologic for treatment of these diseases. Moreover, a considerable number of case reports and pilot studies of off-label use of tocilizumab point to the beneficial effects of tocilizumab for a variety of other phenotypically different autoimmune and chronic inflammatory diseases. Elucidation of the source of IL-6 and of mechanisms through which IL-6 production is dysregulated can thus be expected to lead to clarification of the pathogenesis of various diseases.     

Toll样受体4在实验性自身免疫性葡萄膜炎发病中的作用

目的:研究常见感染菌菌壁成份脂多糖(LPS)在自身免疫性眼病-葡萄膜炎的致病作用.方法:用视网膜抗原IRBP和福氏完全佐剂免疫B10.RⅢ小鼠,诱发实验性自身免疫性葡萄膜炎(EAU),在免疫动物同时添加LPS.免疫19天后检查迟发型变态反应(DTH);21天处死小鼠,收集腹股沟淋巴结和髂动脉淋巴结细胞,检测抗原特异性T淋巴细胞增殖和炎症细胞因子的分泌.结果:LPS加重B10.RⅢ小鼠EAU的发病;增强DTH反应;增加抗原特异性T淋巴细胞增殖和IL-17、IFN-γ的分泌.结论:LPS能够促进EAU发病,从而证明病原微生物感染可能参与如葡萄膜炎等自身免疫性疾病的发生.     

转录因子EB和自噬在神经退行性疾病发病机制中的作用

自噬广泛存在于真核细胞中,与机体生理和病理过程的发生发展密切联系.自噬主要参与长寿蛋白质的降解,以清除受损或多余的蛋白质和细胞器,是细胞自我降解的过程之一.自噬通常被分为三类:大自噬、分子伴侣介导的自噬和小自噬.自噬溶酶体途径(ALP)功能障碍导致蛋白质聚集,从而产生异常蛋白质和无效细胞器的积累,这些特征是阿尔茨海默病(Alzheimer disease,AD)、帕金森病(Parkinson disease,PD)和亨廷顿病等神经退行性疾病(Huntington disease,HD)的标志.自噬的过程受一系列复杂的信号分子的调控,其中一个主要调节因子是转录因子EB(TFEB),是转录因子MiT家族的成员之一.研究表明,TFEB可通过积极调节自噬体形成和自噬体-溶酶体融合参与自噬,此外它还通过溶酶体胞吐作用提高细胞内的清除作用.因此作为自噬溶酶体生物发生的主要调节因子,TFEB已被广泛证明激活后可以从病理方面改善这些疾病.我们回顾分析ALP和TFEB的调节及其对神经退行性疾病的影响,同时展望ALP和TFEB在疾病病理中的复杂作用及其治疗意义.     

Role of Ubiquitin Protein Ligases in the Pathogenesis of Polyglutamine Diseases

The accumulation of intracellular protein deposits as inclusion bodies is the common pathological hallmark of most age related neurodegenerative disorders including polyglutamine diseases. Appearances of aggregates of the misfolded mutant disease proteins suggest that the cells are unable to efficiently degrade them, and failure of clearance leads to the severe disturbances of the cellular quality control system. The quality control ubiquitin ligases are now increasingly implicated in the biology of polyglutamine diseases, Parkinson’s diseases, Amyotrophic lateral sclerosis and Alzheimer’s disease. Here we review the recent studies that have revealed a critical role of E3 ubiquitin ligases in understanding the pathogenesis of polyglutamine diseases.     

溶酶体离子通道蛋白在神经退行性疾病发生发展中的作用及机制研究

溶酶体离子通道蛋白异常引起溶酶体功能障碍是导致阿尔茨海默病(Alzheimer’s disease,AD)和帕金森病(Parkinson’s disease,PD)等神经退行性疾病的重要因素.溶酶体离子通道蛋白调节溶酶体内离子稳态、溶酶体膜电压以及溶酶体的酸度.溶酶体离子通道蛋白的结构或功能缺陷会引起溶酶体降解功能障碍,导致神经退行性疾病的发生发展.在这篇综述中,我们总结了各种离子通道蛋白调节溶酶体功能的过程及机制,以及离子通道蛋白异常参与神经退行性疾病的过程和机制.调节离子通道蛋白改善溶酶体的功能、促进异常聚集蛋白的清除,是神经退行性疾病治疗的潜在途径.     

Role of IL-6 in Asthma and Other Inflammatory Pulmonary Diseases

The incidence and severity of chronic lung diseases is growing and affects between 100 and 150 million people worldwide and is associated with a significant rate of mortality. Unfortunately, the initial cause that triggers most chronic lung diseases remains unknown and current available therapies only ameliorate, but do not cure the disease. Thus, there is a need for identification of new targets and development of novel therapies especially for those most severely affected. IL-6, like other inflammatory cytokines, has been shown to be elevated in different lung diseases, but it was considered a byproduct of ongoing inflammation in the lung. However, recent studies support a dissociation of IL-6 from inflammation in the lung and suggest that this cytokine plays an active role in pathogenesis of asthma and, in all likelihood, COPD. IL-6 may therefore be a germane target for treatment of these and other chronic lung disease. Here, we provide an overview of the studies in mouse models and human patients that provide support for the involvement of IL-6 in lung diseases.     

细胞因子在1型糖尿病中的作用

1型糖尿病是T细胞介导的以胰腺β细胞特异性损伤为特征的炎症性自身免疫疾病,侵润胰岛的巨噬细胞,淋巴细胞等产生的细胞因子如白细胞介素-1β、肿瘤坏死因子-α、干扰素-α、干扰素-γ、肿瘤坏死因子-β和白细胞介素-2等通过诱导胰腺β细胞凋亡/坏死和胰岛素分泌缺陷、调节T细胞的活化和种群比例,以及调控T细胞对β细胞的免疫识别和杀伤等,在1型糖尿病的发生和发展中起关键作用。     

硫化氢在心血管保护过程中免疫炎症调节研究进展

硫化氢(hydrogen sulfide,H_2S)是一种无色、具有臭鸡蛋气味的气体,过去认为只是一种有毒的气体。近年来大量研究证实H_2S是继一氧化氮(nitric oxide,NO)和一氧化碳(carbon oxide,CO)后第三种内源性气体信号分子,同时,H_2S在心血管系统疾病发生、发展过程中起关键的调控作用,但其机制还不明确,已有报道主要通过抗凋亡、抗氧化、调节内皮一氧化氮合酶活性、促进血管新生等;而本文总结了H_2S在缺血性心脏病、动脉粥样硬化等心血管疾病中免疫炎症调节作用及其机制,从而为H_2S生物学功能以及相关心血管疾病的防治提供新的思路。